-
1.
公开(公告)号:WO9605838A2
公开(公告)日:1996-02-29
申请号:PCT/EP9503125
申请日:1995-08-07
Applicant: HOECHST AG , SCHOENHARTING MARTIN , MUELLNER STEFAN , ZABEL PETER
Inventor: SCHOENHARTING MARTIN , MUELLNER STEFAN , ZABEL PETER
IPC: A61K38/00 , A61K31/195 , A61K31/44 , A61K31/52 , A61K31/55 , A61K31/70 , A61K38/13 , A61K45/06 , A61P1/16 , A61P3/06 , A61P3/08 , A61P11/00 , A61P17/00 , A61P27/16 , A61P29/00 , A61P37/06 , A61P37/08
CPC classification number: A61K31/522 , A61K31/554 , A61K38/13 , A61K45/06 , Y10S514/826 , Y10S514/885 , Y10S514/889 , A61K31/4375 , A61K31/4422 , A61K31/277 , A61K2300/00
Abstract: A combined preparation contains a compound with a phosphodiesterase inhibiting effect and a compound that reduces the biologically effective intracellular Ca content. This preparation is suitable for treating immune diseases. Such a preparation can, for example, contain the following combinations: pentoxifylline and nifedipine, pentoxifylline and diltiazem, pentoxifylline and verapamil, pentoxifylline and cyclosporine A, as well as vincopectine and diltiazem.
Abstract translation: 一种组合产品,其包括其中有一个磷酸二酯酶抑制作用的化合物,并且这降低了生物学有效细胞内Ca的化合物<2 +> - 降低含量,适用于免疫疾病的治疗。 实例包括下列组合:己酮可可碱和硝苯地平,己酮可可碱和地尔硫卓,己酮可可碱和维拉帕米,己酮可可碱和环孢菌素A,和长春西汀和地尔硫卓。
-
公开(公告)号:CA2085831C
公开(公告)日:2006-05-30
申请号:CA2085831
申请日:1992-12-18
Applicant: HOECHST AG
Inventor: KRAMER WERNER , MUELLNER STEFAN , GUTWEILER MATTHIAS , KROGGEL MATTHIAS
IPC: A23L1/30 , C07J41/00 , A23L29/275 , A61K31/375 , A61K31/56 , A61K31/78 , A61K31/785 , A61K47/32 , A61P1/16 , A61P3/06 , A61P9/10 , C07J9/00 , C07J31/00 , C07J43/00 , C08F12/00 , C08F12/02 , C08F12/26 , C08F16/14 , C08F16/16 , C08F16/26 , C08F16/36 , C08F16/38 , C08F18/02 , C08F20/26 , C08F20/52 , C08F20/54 , C08F20/58 , C08F22/40 , C08F26/02 , C08F26/10 , C08F220/28 , C08F226/10 , C11D1/02 , C11D3/384
Abstract: Polymeric and oligomeric bile acids are described which can be prepared by polymerization of monomeric bile acids of the formula I G-X-A (I) in which G, X and A have the given meanings or by copolymerization with a monomer of the formula IV in which R9 and R10 have the given meanings, or by copoly- merization with N-vinylpyrrolidone or its derivatives, and/or by copolymerization with ethylenically unsaturated dicarboxylic anhydrides and ethylenically unsaturated dicarboxylic acids each having 2 to 6 carbon atoms; their esters or half esters, alkyl esters having 1-6 carbon atoms, cycloalkyl esters having 5 to 8 carbon atoms, benzyl esters or phenyl esters being understood as esters. They can be used as pharmaceuticals, foodstuff additives, formulation auxiliaries and detergents.
-
公开(公告)号:SI0777482T1
公开(公告)日:2002-04-30
申请号:SI9530551
申请日:1995-08-07
Applicant: HOECHST AG
Inventor: SCHOENHARTING MARTIN , MUELLNER STEFAN , ZABEL PETER
-
公开(公告)号:DE59209745D1
公开(公告)日:1999-10-21
申请号:DE59209745
申请日:1992-11-23
Applicant: HOECHST AG
Inventor: FRICK WENDELIN , MUELLER GUENTER , MUELLNER STEFAN , BREIPOHL GERHARD
IPC: A61K38/28 , A61K38/00 , A61P3/08 , A61P3/10 , C07K5/06 , C07K5/065 , C07K5/08 , C07K5/087 , C07K5/093 , C07K5/097 , C07K7/06 , C07K7/08 , C07K9/00
Abstract: Peptides with insulin-like activity and the formula I where C is a hydrogen atom, amino-acid residue, substituted amino-acid residue or sugar residue, D is an amino-acid residue, phosphoamino-acid residue, sugar residue, covalent bond or hydroxyl radical, E is a hydrogen atom, hydroxyl radical, substituted sugar residues, substituted alkyldiamine or glycerol residue, R is (C1-C4)-alkyl, =O or -O-(C1-C4)-alkyl, R is a sulphur protective group, SO2, SO3, (C1-C3)-alkyl, O2 radical, O3 radical, or hydrogen atom, R or R is, independently of one another, hydrogen or methyl, and W is an integer 1 or 2, the preparation and use thereof for the treatment of diabetes mellitus or non-insulin-dependent diabetes are described.
-
公开(公告)号:CA2212207A1
公开(公告)日:1998-01-31
申请号:CA2212207
申请日:1997-07-30
Applicant: HOECHST AG
Inventor: MUELLNER STEFAN , DAX CLAUDIA
IPC: C07D213/40 , A61K31/165 , A61K31/275 , A61K31/41 , A61K31/42 , A61K31/421 , A61K31/435 , A61K31/44 , A61K31/4418 , A61K31/445 , A61K38/13 , A61K45/00 , A61K45/06 , A61P1/00 , A61P9/08 , A61P9/10 , A61P11/00 , A61P13/02 , A61P13/12 , A61P15/00 , A61P17/00 , A61P25/00 , A61P29/00 , A61P31/04 , A61P31/12 , A61P37/00 , A61P43/00 , C07D213/75 , C07D263/34 , C07D413/12
Abstract: Use of isoxazole and crotonamide derivatives for the modulation of apoptosis Compounds of the formula I or II (see fig.I) (see fig.II) are suitable for the production of pharmaceuticals for the modulation of apoptosis. These compounds can be employed for the treatment of infarct, stroke, neurodegeneration of hypertrophic disorders.
-
公开(公告)号:CA2212205A1
公开(公告)日:1998-01-31
申请号:CA2212205
申请日:1997-07-30
Applicant: HOECHST AG
Inventor: DAX CLAUDIA , MUELLNER STEFAN
IPC: C07D473/04 , A01N37/34 , A61K31/445 , A61K31/52 , A61K31/522 , A61K48/00 , A61K49/04 , A61P1/00 , A61P9/00 , A61P11/00 , A61P13/02 , A61P15/00 , A61P21/00 , A61P25/00 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/00 , A61P37/04 , A61P43/00 , B32B27/34 , C07C29/149 , F24F6/08 , G03G5/047
Abstract: Use of xanthine derivatives for the modulation of apoptosis Compounds of the formula I (see fig.I) where one of the radicals R1 and R3 is a radical of the formula II -(CH2)n-A-CH3 (II) in which A is a covalent bond, -C(O)- or -C(R4)(OH)-, are suitable for the production of pharmaceuticals for the modulation of apoptosis. A combination preparation comprising a compound of the formula I and a compound of the formula IV and/or V (see fig.IV) (see fig.V) is suitable for the production of pharmaceuticals for the modulation of apoptosis.
-
公开(公告)号:NO301427B1
公开(公告)日:1997-10-27
申请号:NO932634
申请日:1993-07-21
Applicant: HOECHST AG
Inventor: AHLERS MICHAEL , GLOMBIK HEINER , GRABLEY SUSANNE , GRANZER ERNOLD , MUELLNER STEFAN , WALCH AXEL , XU GUAN-YU
IPC: A23L33/00 , A61K31/785 , A61K47/30 , A61P3/06 , A61P3/12 , C08F8/12 , C08F26/00 , C08F226/02 , C08F26/02 , A23L1/058
Abstract: The invention relates to polyvinylamine derivatives containing hydrophilic centres, of the formula I in which R , R , R , X, w, x, y and z are as defined, and to a process for their preparation, and to the use of these compounds as medicaments (drugs, pharmaceuticals), active compound (active ingredient) carriers and as foodstuff auxiliaries. The preparation starts, in particular, from highly pure polyvinylamines containing the recurring unit of the formula Ia whose preparation is likewise described.a
-
公开(公告)号:NO301018B1
公开(公告)日:1997-09-01
申请号:NO932635
申请日:1993-07-21
Applicant: HOECHST AG
Inventor: AHLERS MICHAEL , GLOMBIK HEINER , MUELLNER STEFAN , WALCH AXEL
IPC: A61P3/06 , C08F8/12 , A61K31/785 , C08F26/00 , C08F26/02 , C08F226/00
Abstract: The invention relates to crosslinked, nitrogen-containing vinyl copolymers containing units of the formula I and the physiologically acceptable salts thereof, where, in formula I, A1, A2, R, w, x, y and z are as defined, to a process for their preparation, and to the use of the compounds as medicaments (drugs, pharmaceuticals), active compound (active ingredient) carriers and as foodstuff auxiliaries.
-
公开(公告)号:HRP940751A2
公开(公告)日:1997-04-30
申请号:HRP940751
申请日:1994-10-25
Applicant: HOECHST AG , RUHRCHEMIE AG
Inventor: KRAMER WERNER , WESS GUENTHER , MUELLNER STEFAN , NEUBAUER HORST
Abstract: The invention relates to bile acid derivatives of the formula I G1-X-G2(I) in which G1 and G2 are bile acid radicals or modified bile acid radicals in the form of the free acids, the esters or amides, the salt forms and also the forms derivatized on the alcohol groups and X is a bridge group or a single covalent bond, it being possible for G1 and G2 to be optionally bonded via X. The compounds according to the invention have a high affinity for the specific bile acid transport system of the small intestine and inhibit bile acid absorption in a concentration-dependent and competitive manner.
-
10.
公开(公告)号:ZA96540B
公开(公告)日:1996-08-15
申请号:ZA96540
申请日:1996-01-24
Applicant: HOECHST AG
Inventor: GRAEVE ROLF , THORWART WERNER , RAISS RUTH , WIETHMANN KLAUS ULRICH , MUELLNER STEFAN
IPC: A61K31/66 , A61K31/665 , A61P9/00 , A61P29/00 , A61P43/00 , B01J23/44 , B01J25/02 , B01J31/02 , C07F9/38 , C07F9/40 , C07F9/58 , C07F9/6533 , C07F9/655 , C07F9/6553 , C07F9/6571 , C07F9/6574 , C07F9/6596 , C07F , C07D , A61K
Abstract: Medicaments contg. an amino-, cyano- or carboxy-substd. phenylalkane- or phenylalkene-phosphonic acid deriv. of formula (I) and/or its salt and/or stereoisomer are claimed. R1, R2 = R' or R"; or R1+R2 = OCH2O or OCH2CH2O; R3 = H or as for R2; R5 = CN, CH2NHR9 or COOR10; or R1+R5 are bonded, to give a bicyclic cpd. of formula (Ia); R6, R7 = H or 1-6C alkyl; or R1+R7 are bonded, to give a bicyclic cpd. of formula (Ib); R' = OH, 1-12C alkoxy (opt. monosubstd. by COOH or CO-O-(1-12C) alkyl), 3-12C cycloalkoxy, 3-6C alkenyloxy, 1-3Calkoxy( substd. by 5-7C cycloalkyl, heteroaryl (where the heteroatoms are N, S and/or O), Het or phenyl), benzyloxy (mono- to tri-substd. by halomethyl or 1-3C alkoxy) or phenoxy (mono- to tri-substd. by 1-3C alkoxy); R" = OCOR8, OSO2R8, OCH2P(O)(OR8)2 or substd. phenylmethoxy of formula (a); Het = 5 or 6 membered heterocycloalkyl (where the heteroatoms are N, S and/or O, opt. mono- to tri-substd. by 1-3C alkyl); R8 = H or 1-4C alkyl; R9 = H or 2-4C alkanoyl; R10 = H, 1-6C alkyl (opt. substd. by 1-4 of COOH, (1-3C) alkoxy-carbonyl, N(R)2 or morpholino) or trialkylsilyl; R = H or 1-3C alkyl; X-A = (CH=CH-CH=CH-CH) (sic), (CH2CH2CH2CH2CH), (CH2CH2CH2CH2CH), (CH2CH) or (CH=C); heteroatoms are N, S and/or O. Cpds. (I) and their salts and stereoisomers are new, provided that: (1) if R5 = CN, then at most one of R1-R3 = OH; (2) if R10 = H, then none of R1-R3 = OH; (3) if R10 = Me, Et or t-Bu, then R1-R3 are not OMe; (4) the O,O-dimethyl and O,O-diethyl esters of 1-(ethoxycarbonyl)-2-(3,4-methylenedioxyphenyl)-ethanephosphonic acid are excluded; (5) X-A is not (CH2)4CH or (CH=CH-CH=CH-CH); and (6) X-A may also be (CH=CH-CH=C).
-
-
-
-
-
-
-
-
-